The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InRoche announced positive results from its Phase III FENhance 1 study, evaluating the investigational drug fenebrutinib for relapsing multiple sclerosis (RMS). The study demonstrated that fenebrutinib reduced the annualized relapse rate by 51% compared to teriflunomide, confirming its high clinical efficacy. These findings align with the FENhance 2 study, which showed a 59% reduction, effectively translating to approximately one relapse every 17 years. Additionally, the trial met its secondary endpoints, showing statistically significant reductions in brain lesions. As a potential first-in-class BTK inhibitor, fenebrutinib represents a significant advancement in treating both relapsing and primary progressive forms of the disease. Investors view these clinical successes as a strong fundamental driver for Roche's future market position and regulatory approval prospects.